2023. Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s257. DOI:https://doi.org/10.25251/skin.7.supp.257.